2007•MD Conference ExpressRequires access

Imatinib Dose Interruption in GIST: High Progression Risk for 3-YearResponders

Caroline Helwick, Axel Le Cesne

Abstract

This article discusses multiple clinical trials using imatinib for the treatment of gastrointestinal stromal tumor (GIST). Specific topics include the risk associated with the interruption of imatinib therapy among advanced GIST patients, the link between higher doese of imatinib for GIST and longer progression-free survival, as well as the use of imatinib for recurrence-free survival in completely resected GIST.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: GiST, Imatinib, Medicine, Stromal tumor, Oncology, Internal medicine, Imatinib mesylate, Stromal cell